DermTech, Inc. reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed study entitled, ?Non-invasive gene expression analysis rules out melanoma with high negative predictive value regardless of skin phototype? was presented at the Winter Clinical Dermatology Conference (January 12-17, 2024).

Using follow-up information and biopsy results from a large registry database that also served as the basis for the Company?s recently completed Trust 2 Study, this study compared the DMT?s performance in patients with Fitzpatrick skin phototypes I-III (n=4,152) to its performance in patients with skin phototypes IV-VI (n=130). As in prior DMT studies, lesions on acral skin (palms, soles and nailbeds) were excluded because the thicker skin on acral sites may interfere with the test?s non-invasive sample collection method. The negative predictive value (NPV) for both groups (I-III and IV-VI) was greater than 99%, and the 95% confidence interval for the difference in NPV between the groups indicated that there was no significant difference between the skin phototype groups.

Additional analysis limited to subjects with re-examination of DMT-negative lesions at least 6 months after testing confirmed the results observed in the full cohort. These data establish that the DMT?s performance does not vary across Fitzpatrick skin types.